Celldex Therapeutics, Inc (CLDX) Monday reported positive preclinical data for CDX-622, a bispecific antibody targeting inflammation and fibrosis through dual inhibition of thymic stromal lymphopoietin and mast cell depletion via stem cell factor starvation.
The data showed that CDX-622 effectively neutralizes both targets, reducing tissue mast cells and Type 2 inflammatory responses, suggesting potential benefits over single-target therapies.
Presented at the AAAAI Annual Meeting, the findings support the ongoing Phase 1 study in healthy volunteers, which began in November and is actively enrolling. Celldex plans to share initial clinical data later this year.
CLDX is currently trading at $20.96 up 1.90 percent or $0.39 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.